Back to Research

Organization profile

LimmaTech Biologics

LimmaTech Biologics is a clinical-stage Swiss biotechnology company that develops next-generation vaccines to prevent life-threatening infections caused by antimicrobial-resistant (AMR) pathogens. Spun out from GlycoVaxyn, the organization uses a proprietary bioconjugate technology platform based on engineered E. coli to produce multivalent vaccines against Shigella, Gonorrhea, and Staphylococcus aureus.

Schlieren, SwitzerlandFounded 2015

Overview

1. Executive Summary (Confidence: High)

LimmaTech Biologics, based in Schlieren (Zurich), is a global pioneer in the fight against the escalating epidemic of antimicrobial resistance (AMR). Spun out from GlycoVaxyn after that company’s acquisition by GSK in 2015, LimmaTech has maintained a dominant track record in vaccine technology, recently securing a $37 million Series A financing (extended to $40 million) to advance its proprietary pipeline.[23] The organization’s most significant asset is its tetravalent Shigella vaccine (S4V2), which is currently the most clinically advanced of its kind worldwide.[26] In August 2024, LimmaTech entered into a strategic licensing agreement with Valneva, receiving a €10 million upfront payment and eligibility for an additional €40 million in milestones, alongside low double-digit royalties.[28] This partnership validates LimmaTech’s bioconjugate platform as a leading solution for pathogens that have become resistant to traditional antibiotics.[27] The following table summarizes the company’s current pipeline status.

Candidate

Target Pathogen

Clinical Stage

Key Partners/Funding

S4V2

Shigella

Phase 2b (CHIM)

Valneva, Gates Foundation

LBT-SA7

S. aureus (MRSA)

Phase 1 (Start 2024)

AbVacc, CARB-X, NIH

LBT-NG

N. gonorrhoeae

Pre-clinical

CARB-X ($2.2M)

ExPEC

E. coli

Phase 3 (Partnered)

Janssen, GSK, Sanofi

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.